Omnicell to acquire Ateb

MOUNTAIN VIEW, Calif. — In a move that will bring together two companies focused on medication adherence solutions, Omnicell announced Tuesday that it would be acquiring Ateb and its Canadian affiliate Ateb Canada. 

 

The $41 million deal, expected to close in the last quarter of 2016, will bring Ateb’s Time My Meds medication synchronization tool and its pharmacy-based patient care solutions into Omnicell’s portfolio and support its goal of  increasing patient access to medication adherence solutions as a method of improving outcomes, the company said. 

 

“This acquisition demonstrates Omnicell's commitment to supporting the growing shift in how patients receive services along the entire continuum of care, elevating the role of pharmacists in improving overall patient safety and outcomes,” Omnicell president of global automation and medication adherence Rob Seim said. “Ateb’s solutions are currently provided to over 15,000 pharmacies in the U.S. and Canada, and for a quarter of a century the company has been helping pharmacists—who are the most visible and accessible care providers in the community—fulfill their mission of serving patients.”

 

Omnicell said that with the number of patients with at least one chronic condition requiring medication therapy expected to hit 157 million by 2020, the combination of Ateb’s med sync expertise and Omnicell’s adherence packaging will allow pharmacists to better scale their adherence programs. 

 

“As the leader in helping pharmacies develop synchronization programs that improve the health of their patients, we believe today’s announcement will help our customers continue to grow their adherence programs for the benefit of their patients,” Ateb CEO Frank Sheppard said. “This integration creates a clear path between the various stages of successful adherence programs and is an instrumental step in making these offerings a more routine and expected component of outpatient care.”